MedWatch

FDA panel sees cardiovascular benefits from Novo's Victoza

With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.

Novo Nordisk flag

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Græske politikere skal undersøges i Novartis-sag

Det græske parlament har besluttet at nedsætte et særligt udvalg, der skal undersøge politikernes rolle i den påståede Novartis-skandale. Novartis’ græske direktør betvivler, at den overhovedet har fundet sted.

Related articles